Latest filing published 07 Apr 2026 for OmniAb, Inc., €9,125.
Charles S. Berkman (board member) discloses dealings in 3 companies, chiefly Ligand Pharmaceuticals Inc, OmniAb, Inc. and OmniAb Operations, Inc. In total, 66 filings cover trades dated from 11 February 2016 to 7 April 2026.
On the market, this insider has only sold: 5 sales, €6.1M in total. Outside the open market, there are 32 share grants and 25 option exercises. So far in 2026, the count stands at no purchases and 1 sale.
The newest entry dates from 7 April 2026: an open-market sale of €9,125, in OmniAb, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 66 declarations